Aclaris reports positive Phase 1a data for ATI-052 (half-life ~45 days) and picks lichen planus for ATI-2138

Aclaris Therapeutics, Inc.

ATI-052 half-life ~45 days; complete inhibition of CCL17/TARC sustained at least 20 weeks post-dose.
Phase 1a ATI-052 well tolerated; no conjunctivitis or safety signals; dose proportional PK observed.
Phase 1b trials in asthma and atopic dermatitis enrolling; top line results expected H2 2026.
Phase 2b for ATI-052 targeting asthma planned for Q4 2026; Phase 2b ATI-2138 in lichen planus starts H2 2026.
ATI-2138 is a potential first-in-class oral ITK/JAK3 inhibitor addressing pathogenic T cells; no FDA-approved LP therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.